Search | Clinical Trials Finder

Conditions: Breast Cancer
Interventions: TOL2506, Tamoxifen, Letrozole tablets, Anastrozole Tablets, Exemestane Tablets; Drug
Lead sponsor: Tolmar Inc.; Industry
Eligibility: 18 Years to 51 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 17
States / cities: Greenbrae, California • Fort Lauderdale, Florida • Lexington, Kentucky + 14 more

Conditions: Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage IIIA, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer
Interventions: TheraBionic P1 Device; Device
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 22 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 8
States / cities: Clarkston, Michigan • Detroit, Michigan • Farmington Hills, Michigan + 5 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, HER2-Positive Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Electronic Health Record Review, Survey Administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 5
States / cities: Goodyear, Arizona • Duarte, California • Irvine, California + 2 more

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study, Vismodegib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 3
States / cities: Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan

Conditions: Ovarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer, Triple-Negative Breast Cancer, Fallopian Tube Cancer
Interventions: ABT-888, Cyclophosphamide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 9
States / cities: Davis, California • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: Advanced Triple Negative Breast Cancer
Interventions: N-803, PD-L1 t-haNK, Sacituzumab Govitecan-Hziy, Cyclophosphamide; Biological · Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions: Dapagliflozin 10Mg Tab; Drug
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Advanced Solid Tumors Cancer
Interventions: Livmoniplimab, Budigalimab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 21
States / cities: Springdale, Arkansas • Duarte, California • Irvine, California + 16 more

Conditions: Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Biomarker Analysis, Enzalutamide, Pharmacological Study, Taselisib; Other · Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 12
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 9 more

Conditions: Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of the Breast, Neoplasms, Breast, Tumors, Breast
Interventions: Eribulin, Doxorubicin, Cyclophosphamide, Pegfilgrastim; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Atlanta, Georgia • Madison, Wisconsin

Conditions: Breast Cancer, Early-Onset
Interventions: Neoadjuvant chemotherapy administered before surgical extraction of a tumor, Observational; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 12
States / cities: Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 7 more

Conditions: Gastric Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
Interventions: KK-LC-1 TCR-T cells, Aldesleukin; Biological · Drug
Lead sponsor: Christian Hinrichs; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 2
States / cities: New Brunswick, New Jersey

Conditions: TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions: Trilaciclib, Placebo, Gemcitabine, Carboplatin; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more

Conditions: HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Triple Negative Breast Neoplasms, HER2 Mutations Breast Neoplasms
Interventions: ladiratuzumab vedotin, Trastuzumab; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 38
States / cities: Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 30 more

Conditions: Metastatic Breast Cancer
Interventions: WX-671, placebo; Drug
Lead sponsor: Heidelberg Pharma AG; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania

Conditions: Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer, Early Stage Breast Cancer
Interventions: There are no interventions in this observational study.; Other
Lead sponsor: Tempus AI; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 16
States / cities: Birmingham, Alabama • Whittier, California • Weston, Florida + 13 more

Conditions: Breast Cancer, Triple Negative Breast Cancer
Interventions: Sodium (Na) Magnetic Resonance Imaging (MRI), Dynamic Contrast- Enhanced (DCE) MRI; Diagnostic Test
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Paclitaxel, Carboplatin, Sunitinib; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 14
States / cities: Fort Lauderdale, Florida • Fort Myers, Florida • Gainesville, Georgia + 9 more

Conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma, Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer
Interventions: JANX008; Drug
Lead sponsor: Janux Therapeutics; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 18
States / cities: Duarte, California • Sacramento, California • San Diego, California + 15 more

Conditions: Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Interventions: Datopotamab Deruxtecan; Drug
Lead sponsor: Nancy Lin, MD; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Miami, Florida • Boston, Massachusetts • Durham, North Carolina

Conditions: Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Carcinoma, Glioblastoma Multiforme
Interventions: ABBV-221; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts • San Antonio, Texas

Conditions: Triple-Negative Breast Cancer (TNBC)
Interventions: BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Standard-of-care chemotherapy, Losartan and aspirin; Drug
Lead sponsor: BreakBio Corp; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer, Gastric Cancer, Hepatecellular Carcinoma, NSCLC (Advanced Non-small Cell Lung Cancer), Mesothelioma, Pancreatic Carcinoma Metastatic, Hormone Refractory Prostate Cancer, Soft Tissue Sarcomas
Interventions: SHY-ONC6; Drug
Lead sponsor: SHY Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Scottsdale, Arizona • Denver, Colorado • Houston, Texas + 1 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Breast Biopsy Procedure, Carboplatin, Cyclophosphamide, Darolutamide, Doxorubicin, Epirubicin, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Surgical Procedure, Ultrasound Imaging; Procedure · Drug · Biological
Lead sponsor: Vandana Abramson; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

A Study of the TheraBionic P1 Device in Breast Cancer

Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

Phase II ABT-888 With Cyclophosphamide

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC